|Medical news of Remedium.ru portal is the most update information on pharmaceutical and medical equipment market|
Home / News
Russia's Non-Small-Cell Lung Cancer Drug Market Will Grow to $163 Million in 2015The Incidence of Non-Small-Cell Lung Cancer in Russia is the Highest Among the BRIC Markets, According to a New Report from Decision Resources
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the Russian market for non-small-cell lung cancer therapies will grow 3 percent annually from 2010 to 2015 to $163 million in 2015. According to the Emerging Markets report, Non-Small-Cell Lung Cancer in Russia, an increase in the incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents will promote this growth.
The incidence of non-small-cell lung cancer in Russia is the highest among the BRIC (Brazil, Russia, India, China) markets and is comparable to that of the United Kingdom and the United States. Increasing risk of non-small-cell lung cancer due to increasing smoking prevalence in men, in conjunction with an aging population, will drive an increase in incident non-small-cell lung cancer cases in Russia.
"As the incident non-small-cell lung cancer population grows in Russia, sales of most drug classes are expected to grow through 2015," said Decision Resources Analyst Natalia Reoutova, M.A., M.Sc. "The most dramatic growth will likely be seen in the kinase inhibitors drug class where three emerging agents--Boehringer Ingelheim's Tovok, Pfizer's dacomitinib and ArQule/Daiichi Sankyo/Kyowa Hakko Kirin's tivantinib--should make their debut in or before 2015."
The new report features extensive primary research with Russian oncologists as well as a market outlook by drug and class through 2015 and non-small-cell lung cancer epidemiology through 2020.
About Emerging Markets Reports
Decision Resources is the first and only company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.